January 12, 2018
This week, we provide top-five ranked VE data for our Medical Sector stocks. We take a look at our latest data on JPMorgan Chase $JPM and provide a free download link for our stock report on the company. Because overvaluation has crept up again, we now have another Valuation Watch. VALUATION WATCH: Overvalued stocks now make up 63.42% of our stocks assigned a valuation and 26.95% of those equities are calculated to be overvalued by 20% or more. Because overvaluation has once again increased above 60%, we have re-insitituted a Valuation Watch. Fifteen sectors are calculated to be overvalued.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Index
|
Week Open
|
Friday PM
|
Change
|
% Change
|
YTD
|
DJIA |
25308.4 |
25759.55 |
451.15 |
1.78% |
4.21% |
NASDAQ |
7135.38 |
7251.92 |
116.54 |
1.63% |
5.05% |
RUSSELL 2000 |
1559.8 |
1590.76 |
30.96 |
1.98% |
3.60% |
S&P 500 |
2742.67 |
2783.25 |
40.58 |
1.48% |
4.10% |
ValuEngine Market Overview
Summary of VE Stock Universe |
|
Stocks Undervalued |
36.58% |
Stocks Overvalued |
63.42% |
Stocks Undervalued by 20% |
16.76% |
Stocks Overvalued by 20% |
26.95% |
ValuEngine Sector Overview
Sector
|
Change
|
MTD
|
YTD
|
Valuation
|
Last 12-MReturn
|
P/E Ratio
|
| Aerospace | 0.74% |
3.22% |
3.22% |
29.25% overvalued |
27.98% |
23.36 |
| Industrial Products | 1.08% |
2.81% |
2.81% |
16.05% overvalued |
27.32% |
25.51 |
| Computer and Technology | 0.93% |
4.38% |
4.75% |
15.62% overvalued |
35.47% |
33.52 |
| Construction | 1.21% |
4.01% |
4.01% |
15.12% overvalued |
32.43% |
24.37 |
| Multi-Sector Conglomerates | 0.64% |
3.17% |
3.17% |
14.05% overvalued |
20.37% |
21.92 |
| Transportation | 1.26% |
4.37% |
4.37% |
12.05% overvalued |
29.26% |
25.22 |
| Consumer Discretionary | 1.05% |
2.27% |
2.27% |
11.23% overvalued |
27.86% |
26.06 |
| Business Services | 1.07% |
2.99% |
2.99% |
8.93% overvalued |
23.72% |
26.33 |
| Retail-Wholesale | 1.64% |
3.40% |
3.40% |
8.53% overvalued |
18.22% |
25.76 |
| Auto-Tires-Trucks | 1.43% |
5.97% |
5.97% |
7.58% overvalued |
28.87% |
15.88 |
| Finance | 0.60% |
2.15% |
2.15% |
7.18% overvalued |
14.28% |
19.12 |
| Medical | 1.24% |
4.10% |
4.10% |
6.80% overvalued |
46.32% |
29.08 |
| Consumer Staples | 0.17% |
0.54% |
0.54% |
5.11% overvalued |
19.21% |
26.68 |
| Basic Materials | 1.22% |
4.82% |
4.80% |
4.22% overvalued |
25.47% |
25.93 |
| Utilities | 0.31% |
-0.20% |
-0.20% |
3.29% overvalued |
10.13% |
22.21 |
| Oils-Energy | 1.97% |
7.72% |
7.72% |
4.44% undervalued |
4.81% |
29.60 |
Sector Talk--Medical
Below, we present the latest data on Medical stocks from our Professional Stock Analysis Service. Top- five lists are provided for each category. We applied some basic liquidity criteria--share price greater than $3 and average daily volume in excess of 100k shares.
Top-Five Medical Stocks--Short-Term Forecast Returns
Ticker |
Name |
Mkt Price |
Valuation (%) |
Last 12-M Return (%) |
TEVA |
TEVA PHARM ADR |
21.74 |
6.16% |
-36.58% |
FWP |
FORWARD PHARMA |
4.34 |
N/A |
N/A |
UTHR |
UTD THERAPEUTIC |
142.93 |
20.76% |
0.11% |
MNK |
MALLINCKRODT PL |
22.9 |
-59.62% |
-54.60% |
ENDP |
ENDO INTL PLC |
7.92 |
-71.54% |
-43.47% |
Top-Five Medical Stocks--Momentum
Ticker |
Name |
Mkt Price |
Valuation (%) |
Last 12-M Return (%) |
RCKT |
ROCKET PHARMACT |
12.36 |
N/A |
616.52% |
XOMA |
XOMA CORP |
33.27 |
-15.98% |
597.48% |
MRNS |
MARINUS PHARMA |
7.57 |
N/A |
581.98% |
MDGL |
MADRIGAL PHARMA |
98.84 |
300.00% |
524.38% |
ESPR |
ESPERION THERAP |
69.91 |
262.14% |
450.47% |
Top-Five Medical Stocks--Composite Score
Ticker |
Name |
Mkt Price |
Valuation (%) |
Last 12-M Return (%) |
VRX |
VALEANT PHARMA |
23.81 |
-6.95% |
55.32% |
MYL |
MYLAN NV |
46.71 |
0.38% |
25.30% |
AZN |
ASTRAZENECA PLC |
35.4 |
9.77% |
25.62% |
INVA |
INNOVIVA INC |
14.53 |
-28.66% |
26.35% |
LCI |
LANNETT INC |
24.85 |
-24.31% |
20.63% |
Top-Five Medical Stocks--Most Overvalued
Ticker |
Name |
Mkt Price |
Valuation (%) |
Last 12-M Return (%) |
SAGE |
SAGE THERAPEUTC |
174.6 |
300.00% |
230.37% |
CYH |
COMMNTY HLTH SY |
4.97 |
300.00% |
N/A |
VIVE |
VIVEVE MEDICAL |
4.98 |
300.00% |
N/A |
NKTR |
NEKTAR THERAP |
69.88 |
300.00% |
433.44% |
MDGL |
MADRIGAL PHARMA |
98.84 |
300.00% |
524.38% |
Free Download for Readers
As a bonus to our Free Weekly Newsletter subscribers,
we are offering a FREE DOWNLOAD of one of our Stock Reports
JPMorgan Chase & Co. (JPM) is a financial services firm. The Company is engaged in investment banking, financial services for consumers and small businesses, commercial banking, financial transaction processing, asset management and private equity. It offers various investment banking products and services, including advising on corporate strategy and structure, capital-raising in equity and debt markets, risk management, market-making in cash securities and derivative instruments, prime brokerage. It also offers consumer and business, and mortgage banking products and services that include checking and savings accounts, mortgages, home equity and business loans, and investments. JPMorgan Chase & Co. is headquartered in New York.
VALUENGINE RECOMMENDATION: ValuEngine continues its BUY recommendation on JPMORGAN CHASE for 2018-01-11. Based on the information we have gathered and our resulting research, we feel that JPMORGAN CHASE has the probability to OUTPERFORM average market performance for the next year. The company exhibits ATTRACTIVE Company Size and Sharpe Ratio.
You can download a free copy of detailed report on JPMorgan Chase & Co. (JPM) from the link below.
Read our Complete Rating and Forecast Report HERE.
ValuEngine Forecast |
||
Target Price* |
Expected Return |
|
|---|---|---|
1-Month |
111.38 | 0.49% |
3-Month |
112.15 | 1.18% |
6-Month |
114.45 | 3.25% |
1-Year |
117.37 | 5.89% |
2-Year |
128.45 | 15.89% |
3-Year |
135.09 | 21.88% |
Valuation & Rankings |
|||
Valuation |
17.42% overvalued | Valuation Rank(?) |  31 |
1-M Forecast Return |
0.49% | 1-M Forecast Return Rank | 83 |
12-M Return |
27.29% | Momentum Rank(?) | 71 |
Sharpe Ratio |
0.92 | Sharpe Ratio Rank(?) | 87 |
5-Y Avg Annual Return |
17.78% | 5-Y Avg Annual Rtn Rank | 83 |
Volatility |
19.40% | Volatility Rank(?) | 71 |
Expected EPS Growth |
14.74% | EPS Growth Rank(?) | 44 |
Market Cap (billions) |
414.34 | Size Rank | 100 |
Trailing P/E Ratio |
16.02 | Trailing P/E Rank(?) | 79 |
Forward P/E Ratio |
13.96 | Forward P/E Ratio Rank | 67 |
PEG Ratio |
1.09 | PEG Ratio Rank | 41 |
Price/Sales |
3.70 | Price/Sales Rank(?) | 32 |
Market/Book |
2.03 | Market/Book Rank(?) | 56 |
Beta |
1.23 | Beta Rank | 28 |
Alpha |
-0.00 | Alpha Rank | 52 |
Contact ValuEngine at (800) 381-5576 or support@valuengine.com
Visit www.ValuEngine.com for more information
Contact ValuEngine Capital at info@valuenginecapital.com
Visit www.ValuEngineCapital.com for more information
If you no longer wish to receive this free newsletter, CLICK HERE to unsubscribe
